| 저자(한글) |
Takagi, Kimiaki,Takai, Manabu,Kawata, Kei,Horie, Kengo,Kikuchi, Mina,Kato, Taku,Mizutani, Kosuke,Seike, Kensaku,Tsuchiya, Tomohiro,Yasuda, Mitsuru,Yokoi, Shigeaki,Nakano, Masahiro,Ushikoshi, Hiroaki,M |
| 초록 |
Sorafenib is a tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor (VEGFR) used for advanced renal cell carcinoma. Treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal cell carcinoma. However, in spite of its therapeutic efficacy, sorafenib causes a wide range of adverse events. Cardiovascular adverse events have been observed when sorafenib was used with targeted agents. Although these adverse events like hypertension, reduced left ventricular ejection fraction, cardiac ischemia or infarction were manageable with standard medical therapies in most cases, some had a poor clinical outcome. We report three cases of acute myocardial infarction associated with sorafenib in patients with metastatic renal cell carcinoma. |
